Repare Therapeutics Inc. (NASDAQ:RPTX)
|Dividend Rate (ttm)||0.0000|
|Trading Day||Nov 28|
|Day's Range||Market Closed|
|52 Week Range||8.07 - 27.4|
About Repare Therapeutics Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.
The Company's pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, as well as RP-6306, a CCNE1-SL inhibitor, and a Polθ inhibitor program.
Repare Therapeutics Inc. dividends
Repare Therapeutics Inc has a market cap or net worth of $686.07 million. The enterprise value is $0.
Repare Therapeutics Inc has 41.96 million shares outstanding.
The trailing PE ratio is 0.0000 and the forward PE ratio is -25.7372. Repare Therapeutics Inc's PEG ratio is 0.0000.
Stock Price Statistics
The stock price has decreased by -0.2385%. The beta is 1.4989, so Repare Therapeutics Inc's price volatility has been higher than the market average.
In the last 12 months, Repare Therapeutics Inc had revenue of $0 and earned $0 in profits. Earnings per share was $.